Professional Summary
Professional Overview
Nathalie Scholler is an accomplished Translational Research executive with over 20 years of experience in the biopharmaceutical industry. As the Vice President of Translational Research at TORL BioTherapeutics, LLC, she is responsible for leading the company's efforts to bridge the gap between preclinical research and clinical development, driving the translation of innovative therapies into the clinic.
Experience Summary
Current Role
In her current role as VP of Translational Research at TORL BioTherapeutics, LLC, Nathalie is responsible for overseeing the company's translational research programs, which aim to accelerate the development of novel cancer immunotherapies. She leads a team of cross-functional researchers and collaborates closely with the clinical development and regulatory affairs departments to ensure a seamless transition from the lab to the clinic.
Career Progression
Prior to her current role, Nathalie held several leadership positions in the industry, including Senior Director of Oncology Research at Gilead Sciences and Director of Translational Medicine at Kite, a GILEAD company. In these roles, she has demonstrated a strong track record of driving innovative research initiatives and translating preclinical findings into successful clinical programs.
Nathalie has also held academic appointments, serving as an Adjunct Lecturer at Santa Clara University and an Associate Adjunct Professor at the University of California, Santa Cruz, where she contributed to the training and development of the next generation of bioengineering and translational medicine professionals.
Academic Background
Nathalie holds a Medical Degree from Aix-Marseille II University and has completed postdoctoral fellowships at Bristol-Myers Squibb and the Center of Immunology of Marseille-Luminy (CIML). Her academic background and extensive research experience have positioned her as a thought leader in the field of translational oncology.
Areas of Expertise
Nathalie's areas of expertise include:
- Translational research and biomarker development
- Immuno-oncology and cancer biology
- Biopharmaceutical drug development
- Preclinical and clinical research management
- Cross-functional team leadership and collaboration
Professional Impact
Throughout her career, Nathalie has made significant contributions to the advancement of cancer research and the development of novel immunotherapies. She has been instrumental in the successful translation of several promising drug candidates from the preclinical stage to clinical trials, with a focus on improving patient outcomes and expanding treatment options for individuals affected by cancer.
Conclusion
Nathalie Scholler is a seasoned Translational Research executive with a proven track record of driving innovation and leading high-performing teams in the biopharmaceutical industry. Her deep expertise in oncology research and her ability to bridge the gap between preclinical and clinical development make her a valuable asset to TORL BioTherapeutics, LLC as the company continues to advance its portfolio of cancer immunotherapies.
